The QualityStocks Daily Tuesday, December 7th, 2021

Today's Top 3 Investment Newsletters

SmallCapRelations(SYTA) $4.6000 +66.67%

QualityStocks(TMMI) $0.0140 +42.14%

MarketClub Analysis(TRUP) $155.4100 +39.03%

The QualityStocks Daily Stock List

International Isotopes, Inc. (INIS)

QualityStocks, MarketBeat, SmallCapVoice and Orbit Stocks reported earlier on International Isotopes, Inc. (INIS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

International Isotopes, Inc. manufactures a comprehensive collection of nuclear medicine calibration and reference standards, and an assortment of cobalt-60 products, including teletherapy sources. The OTCQB-listed Company also provides a broad array of radiological field services on a contract basis to clients. Additionally, International Isotopes provides a wide-ranging selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications. International Isotopes has its corporate office in Idaho Falls, Idaho.

The Company is working to advance its planned environmentally friendly, green technology, uranium de-conversion and fluorine extraction processing facility in Lea County, which is roughly 15 miles west of Hobbs, New Mexico. The new facility will be on a 640-acre site. The Company’s belief is that this new commercial facility will provide a first-rate commercial opportunity.

International Isotopes holds patents that give it exclusive rights for the Fluorine Extraction Process (FEP). This process produces high value, high purity fluoride gasses in union with uranium de-conversion. The Company exclusively owns the patents for the fluorine extraction process.

International Isotopes has developed a unique process to convert depleted uranium tails (the by-product produced from the enrichment of uranium) to ultra-high purity, high value industrial fluoride products. The Company’s’ business segments include the Depleted Uranium De-Conversion and Fluorine Extraction Process (FEP) Project; Radiochemicals for Cancer Treatment; Nuclear Medicine Reference and Calibration Standards; Medical Teletherapy Products, AOS Series Type B (U) Transportation Containers, and Transportation Services.

International Isotopes’ de-conversion process will convert the DUF6 by-product (or tails) from uranium enrichment operations into depleted uranium tetrafluoride (DUF4). The Company will then employ its patented FEP technology to extract fluorine from the DUF4 for use in the manufacture of specialty, high-value fluoride gases.

International Isotopes, Inc. (INIS), closed Tuesday’s trading session at $0.1, up 35.318%, on 2,091,935 volume. The average volume for the last 3 months is 2.092M and the stock's 52-week low/high is $0.04/$0.34.

IGEN Networks Corp. (IGEN)

QualityStocks, SmallCapVoice, RedChip, The Green Baron, StockGuru, Equities.com, equities Canada and MarketBeat reported earlier on IGEN Networks Corp. (IGEN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

IGEN Networks Corp. is a foremost innovator of cloud-based and Internet of Things (IoT) automotive solutions for the protection and management of mobile assets. The Company provides peace-of-mind to automotive consumers and their families via direct access to IoT cloud-based services, which include Stolen Vehicle Protection, Real-time updates on asset health and Driver Behavior. OTCQB-listed and incorporated in 2006, IGEN Networks has its head office in Murrieta, California.

The Company provides vehicle tracking and recovery solutions to the automotive dealership industries in the U.S. IGEN Networks serves the automobile industry through vehicle security services, lot management services, and driver behavior services.

IGEN Networks enables automotive dealer channels to provide new products, create additional revenue streams, as well as keep their customers. The Company provides peace-of-mind to consumers through providing direct access to vehicle status and driver behavior. The Company also enables insurance companies to decrease their rating errors through offering consumers discounted premiums in return for access to vehicle and driver behavior data.

IGEN Networks Corp. (IGEN), closed Tuesday’s trading session at $0.0087, up 58.1818%, on 292,878,929 volume. The average volume for the last 3 months is 292.259M and the stock's 52-week low/high is $0.0029/$0.0243.

Vasta Platform Ltd (VSTA)

QualityStocks, MissionIR, FeedBlitz, PennyStocks24, Tip.us, SmallCapVoice, SeriousTraders, MarketBeat, HotStockChat, StreetInsider, Information Solutions Group, InvestorPlace, Momentum Hunter, CenturyStocks, Pumps and Dumps, Wealth Insider Alert, Tiny Gems, Wall St Insider Stocks and Penny Stock Rumble reported earlier on Vasta Platform Ltd (VSTA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vasta Platform Ltd (NASDAQ: VSTA) is an education firm that is engaged in the provision of digital and educational solutions to private schools which operate in Brazil’s K-12 educational sector.

The firm has its headquarters in Sao Paulo, Brazil and was incorporated in 1966. The firm serves consumers in Brazil.

The company believes that it is uniquely positioned to help learning institutions in Brazil undergo the process of digital transformation and enhance their education skill-set to the 21st century. It promotes the unified use of technology in K-12 education with improvements in quality, efficiency and production, increased collaboration among support staff and actionable insight and enhanced data for educators.

The enterprise operates through the Digital Platform and EdTech platform segments. The former segment comprises of a digital and physical e-commerce platform known as LivroFácil as well as other digital services. On the other hand, the EdTech segment provides complementary and core educational content solutions through printed and digital content, which includes learning systems, textbooks and other complimentary educational services. The enterprise is involved in the operation of an e-commerce channel that sells educational content, which includes stationery, school materials and others. This is in addition to providing university admission preparatory exam courses. The enterprise serves different stakeholders, including private school owners, administrators, educators, parents and students.

The firm recently entered into a distribution agreement with Instituto Presbiteriano Mackenzie, which will make it the exclusive and only distributor of the latter company’s learning system. This long-term contract will have a positive effect on investments into the firm while also helping to extend its consumer reach.

Vasta Platform Ltd (VSTA), closed Tuesday’s trading session at $2.98, up 2.4055%, on 435,429 volume. The average volume for the last 3 months is 435,385 and the stock's 52-week low/high is $2.20/$15.86.

Chindata Group (CD)

MarketBeat, StreetInsider, Trades Of The Day and StocksEarning reported earlier on Chindata Group (CD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Chindata Group Holdings Ltd (NASDAQ: CD) (FRA: 5WV) is a data center solution provider that is engaged in the provision of carrier-neutral hyper scale data center solutions.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 2015 by Jing Ju. Prior to its name change in April 2020, the firm was known as BCPE Bridge Stack Ltd. The firm serves consumers around the globe, with a focus on Southeast Asia, India and China.

The company leverages its research and development capabilities, strong design expertise and efficient supply chain management to create long-term partnerships with leading technology firms in different industry verticals. These partnerships have enhanced the company’s reliability as it focuses on solidifying its leadership and growing its next-generation hyper scale data center presence in emerging markets. The company mainly pursues clients who seek wholesale data center services and capacity.

The enterprise provides online entertainment, smart homes and cities, cloud computing and artificial intelligence, among other on-demand services. It also offers technical and consulting services; rental and internet data center colocation services. Its integrated data center solutions include maintenance and operation, connectivity, power supply, and infrastructure which is tailor-made to their requirements and scale throughout the construction and operation process. The enterprise also offers colocation services at smaller retail data centers in major metro areas.

The firm recently initiated its expansion plan into the Thailand market, which will help extend its consumer reach and bring in more investors into the firm. Currently, it is focused on advancing its hyper scale greenfield development model in the Asia Pacific emerging market.

Chindata Group (CD), closed Tuesday’s trading session at $7.37, up 11.1614%, on 2,366,734 volume. The average volume for the last 3 months is 2.362M and the stock's 52-week low/high is $5.40/$27.47.

iQIYI Inc. (IQ)

MarketClub Analysis, Schaeffer's, MarketBeat, InvestorPlace, The Street, StreetInsider, StocksEarning, Trades Of The Day, Top Pros' Top Picks, Wealth Insider Alert, Kiplinger Today, The Online Investor, Zacks, Daily Trade Alert, InvestmentHouse, Investing Daily, Cabot Wealth, INO Market Report, BUYINS.NET, Market Intelligence Center Alert, AllPennyStocks, QualityStocks, StockMarketWatch and Kiplinger’s Weekly Update reported earlier on iQIYI Inc. (IQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

iQIYI Inc. (NASDAQ: IQ) (FRA: IQ8) is an online entertainment service provider that is engaged in the provision of online entertainment services under its own brand.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in November 2009 by Yu Gong. Prior to its name change in November 2017, the firm was known as Qiyi.com Inc. The firm has forty-nine companies in its corporate family and serves consumers across the globe, with a focus on China.

The company produces original video content and distributes appealing user-generated content, partner-generated content and professionally-produced content. Its revenue is generated from online advertising services and membership services. The company generates most of its revenue from China. It operates as a subsidiary of Baidu Holdings Ltd.

The enterprise provides different services and products which include e-commerce, animations, online literature, live broadcasting, online games, internet video and social media platform. It operates a platform which offers a collection of internet video content. This is in addition to operating an e-commerce platform dubbed iQIYI Mall, which centers on entertainment-related merchandise like VR glasses. It also sells beauty and skincare products, apparel and accessories and electronics. The enterprise also offers a social platform known as iQIYI Paopao; and a live broadcasting service dubbed iQIYI Show, which allows users to follow their favorite shows, celebrities and hosts in real time via live broadcasting.

The firm recently announced its latest financial results for 2021 which show increases in its revenues. Its CEO noted that they were focused on executing its diversified content strategy and improving the efficiency of its operations.

iQIYI Inc. (IQ), closed Tuesday’s trading session at $5.35, up 7.2144%, on 6 volume. The average volume for the last 3 months is 9.386M and the stock's 52-week low/high is $4.58/$28.97.

Knight Therapeutics (KHTRF)

StreetInsider and MarketBeat reported earlier on Knight Therapeutics (KHTRF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Knight Therapeutics Inc. (OTC: KHTRF) (TSE: GUD) (FRA: 04K) is a specialty pharmaceutical firm that is focused on the development, acquisition, licensing, marketing and distribution of consumer health and pharmaceutical products and medical devices.

The firm has its headquarters in Montreal, Canada and was incorporated in 2013, on November 1st by Jonathan R. Goodman. It operates in the healthcare sector and serves consumers in Canada and internationally.

The company focuses on a range of therapeutic areas, which include chronic hepatitis C, fungal infections, inflammatory diseases and oncology. It also invests in financing other life science firms, with the objective of securing product distribution rights.

The enterprise’s products include Nerlynx for the treatment of early-stage breast cancer; Iluvien to treat vision loss caused by diabetic macular edema; Trelstar for the treatment of advanced prostate cancer and for pain linked to endometriosis; Ibsrela to treat irritable bowel syndrome with constipation in grownups; Imvexxy for the treatment of postmenopausal dyspareunia; and Bijuva to treat moderate to severe vasomotor symptoms linked to menopause in women with intact uterus. In addition to this, it provides Tobradosa Haler for chronic lung infections; Ursofalk for the treatment of biliary cirrhosis; Cresemba and AmBisome for the treatment of fungal infections; Vidaza for the treatment of myelodysplastic syndrome; and Halaven for the treatment of metastatic breast cancer.

The company recently announced its latest financial results which show increases in its gross margin and revenues. It is focused on delivering on growth and operational excellence, which will have a positive effect on investments into the company.

Knight Therapeutics (KHTRF), closed Tuesday’s trading session at $4.14, up 0.4854%, on 5,200 volume. The average volume for the last 3 months is 5,200 and the stock's 52-week low/high is $3.9452/$4.6434.

TMM Inc. (TMMI)

QualityStocks, PennyStocks24 and SmallCapVoice reported earlier on TMM Inc. (TMMI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TMM Inc. (OTC: TMMI) is a technology firm that is focused on the development and distribution of TRUDEF digital video compression technology.

The firm has its headquarters in Wilmington, Delaware and was incorporated in 1986, on October 8th. Prior to its name change in 2001, the firm was known as Total Multimedia Inc. The firm serves consumers in the United States.

The company is focused on improving video image quality and bandwidth utilization. Its digital video compression technology offers content delivery and workflow solutions for reconnaissance, surveillance, intelligence, as well as education, gaming, space exploration, medical imaging, security, defense, mobile, sports, cable TV, streaming media and digital cinema.

The enterprise’s products include a high compression solution with pre-filtering capability for high-def television broadcasting, IPTV and ultra-high definition television markets known as TRUDEF Network Distribution; another compression solution that doesn’t have pre-filtering capability, designed for the Blu-ray disc market dubbed TRUDEF File Based Distribution; and a low compression solution without pre-filtering capability known as TRUDEF Intra Frame, designed for the digital archiving and movie production markets. It also owns a fractal compression technology known as VDK Soft Video, which uses fractal video compression and decompression algorithms.

The firm recently expanded into artificial intelligence after entering into a co-development agreement with Code Baby Inc., a virtual character pioneer company. This move will propel the firm’s growth into diverse markets via the integration of new technologies as well as afford it greater access to a broad base of consumers and businesses, which will be good for its investments.

TMM Inc. (TMMI), closed Tuesday’s trading session at $0.0199, up 42.1429%, on 78,858 volume. The average volume for the last 3 months is 78,858 and the stock's 52-week low/high is $0.0068/$0.108.

Know Labs, Inc. (KNWN)

QualityStocks, MarketBeat, StocksEarning, PoliticsAndMyPortfolio, TradersPro and MarketClub Analysis reported earlier on Know Labs, Inc. (KNWN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Know Labs, Inc. is developing a new technology platform that measures blood glucose non-invasively. The Company invented a pioneering technology called Bio-RFID, which will provide information to consumers about their health and wellness. In addition, Know Labs uses its proprietary ChromaID technology to identify unique molecular signatures in materials. OTCQB-listed, the Company formerly went by the name Visualant, Incorporated. It changed its name to Know Labs, Inc. in May of 2018. Know Labs is based in Seattle, Washington.

The Company develops technology platforms that harness light and radio waves to uncover distinct insights about the world. Its technology directs electromagnetic energy through a substance or material to capture a unique molecular signature.

Know Labs refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio- RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye.

ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers, which may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can undergo integration into an array of wearable, mobile or bench-top form factors.

This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses, which could only formerly be performed by invasive and/or large and expensive lab-based tests. ChromaID and Bio-RFID technologies use electromagnetic energy along the electromagnetic spectrum to perform analytics that enable the user to identify, authenticate, as well as diagnose materials and substances.

Know Labs previously released a white paper detailing the results of an experiment using the Company’s Bio-RFID™ technology to detect differing blood-glucose levels in the human body. The experiment used a tissue phantom mimicking a blood/skin/muscle ratio of roughly 5 percent/10 percent/85 percent respectively to measure varying amounts of glucose in the blood. This experiment produced successful results with the sensor system showing strong signal response and linearity between the varying glucose levels.

Know Labs also released a video presentation of its Bio-RFID™ platform technology’s successful identification of blood alcohol levels. In the video presentation, Chief Executive Officer, Mr. Phil Bosua discusses the Company’s use of Bio-RFID to detect blood alcohol levels. He also discusses the wide-ranging implications for its technology platform.

The transcript of Mr. Bosua’s presentation in the video states in part, “Over the last month we’ve been powering through a ton of experiments and innovations and are really happy to report we’ve now got an AI based algorithm that allows our technology to detect blood alcohol levels non-invasively. So it’s official - Bio-RFID is now a platform technology. Not only can we detect the holy grail of biotech - blood glucose - but also - blood alcohol, and more to come in the future.”

Know Labs, Inc. (KNWN), closed Tuesday’s trading session at $2.07, up 23.2143%, on 40,995 volume. The average volume for the last 3 months is 40,995 and the stock's 52-week low/high is $1.10/$4.83.

Demand Brands (DMAN)

QualityStocks, OTCPicks, The Street, CRWEFinance, CRWEPicks, CRWEWallStreet, Daily Markets, DrStockPick, BestOtc, InvestorPlace, WiseAlerts, PennyOmega, StockHotTips, StreetInsider, Trades Of The Day and Dynamic Wealth Report reported earlier on Demand Brands (DMAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Demand Brands Inc. (OTC: DMAN) is an investment holding firm that is engaged in the provision of marketing solutions.

The firm has its headquarters in California and was incorporated in 1996, on October 22nd. It serves consumers across the globe and operates under the financials industry, in the financial services industry, under the asset management sub-industry.

The enterprise is centered on partnerships, strategic acquisitions and joint ventures with a particular interest in food, CBD, marijuana edibles and hemp, as well as related technology and educational industries.

The company promotes healthy lifestyles for pets, children, women and men and mainly operates in the hemp, cannabis edibles, health and wellness, superfoods and cannabidiol sectors. Its brands include CoCos Pure, Oil of Sunshine, Canadian Organic Popcorn, Weedies Edibles and Infusional. The company markets beverages, vapes, oils and edible products under these brands. This is in addition to engaging in the development of drone program technologies and electro-seismic applications for the energy industry. The company, through Pacific Technology Group Inc., its wholly owned subsidiary, looks for and invests in emerging technology sector businesses.

Demand Brands, through its wholly owned subsidiary, recently entered into an agreement with Viride Research Fund. This move will allow Demand to acquire Viride and other assets which will be marketed under the Lucky Chief brand. The assets include its interests in a dispensary and extraction lab as well as its THC genetics library. Viride is a leading firm in the global marijuana industry. Acquiring synergistic assets will facilitate the advancement of a vertically integrated marijuana-focused consumer packaged business, which may bring in hefty returns and investments.

Demand Brands (DMAN), closed Tuesday’s trading session at $0.0202, up 27.8481%, on 30,417,528 volume. The average volume for the last 3 months is 30.418M and the stock's 52-week low/high is $0.0026/$0.0434.

Fernhill (FERN)

PennyStocks24, QualityStocks, OurHotStockPicks, Xtremepicks, Ironman Stock, Orbit Stocks, Top Stock Tips, HotStockProfits, Pennystocktweeters.com, Market News, Fast Moving Stocks, Hot Stock Profits, InvestorPlace, Center Stage Stocks, Penny Stock Whispers, Real Pennies, RockingPennyStocks, TheMicrocapNews, Xtreme Stock Picks and Penny Stock Rumble reported earlier on Fernhill (FERN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fernhill Corp. (OTC: FERN) is a diversified technology holding firm that seeks to acquire, build and develop software products and has interests in many sectors. These include blockchain/digital assets and mobile applications.

The company is based in Fountain Hills, Arizona and was incorporated in 1997, on April 7th. It is also engaged in partnerships, developments and acquisitions in businesses involved in the energy sector. This is in addition to being involved in the mining and resources sector.

The firm also operates as an entertainment, technology and media firm and is centered on incubating and building Web and mobile applications from different genres, which include entertainment, sports, crypto-currency, real estate, marijuana and Live advice, which mainly use its customizable matching platform. Other sectors the firm is involved in include the alternative energy sector comprising of battery storage (for utility scale, micro grid and electric cars) and solar and Next Generation technologies like artificial intelligence.

The enterprise’s products include the P72 prototype and the PSESU 5000. The latter’s master control unit is a 5000Wh electricity saving unit that has been designed to supply up to 3kilowatts of AC power to multiple mining services.

The firm supports and adheres to the Environmental, Social and Governance (ESG) principles which embody corporate responsibility and forward thinking leadership. The firm believes that a lot of good can be done, even while creating considerable shareholder value. This will attract more investors to the firm, in addition to providing more opportunities for growth and expansion.

Fernhill (FERN), closed Tuesday’s trading session at $0.0283, up 33.1765%, on 30,063,391 volume. The average volume for the last 3 months is 30.063M and the stock's 52-week low/high is $0.0005/$0.066.

Bantec (BANT)

We reported earlier on Bantec (BANT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bantec Inc. (OTC: BANT) is a product and service firm that is focused on the research, design, development, testing, production, distribution and integration of military products which include advanced low altitude unmanned aerial vehicle systems and related technologies across the globe.

The enterprise, which was formerly known as Bantek Inc., provides its services in the United States and operates as part of the Aerospace products and parts manufacturing industry. It has its headquarters in Little Falls, New Jersey and was founded in 1972, on June 26th.

The firm has operations based in Vancouver, Washington as well as West Haven, Connecticut and pursues strategic partnerships and acquisitions with UAV companies. It offers a technological spectrum of drones, which have applications in theatres, agriculture, commercial enterprises, governments and in defense.

In addition to providing construction/environmental services and products and logistics services, the company uses its bantec.store website to sell drones, drone accessories and training services to the U.S. government, security companies, fire departments and law enforcement; to supply replacement and spare parts to commercial customers, U.S military prime contractors and federal government agencies and selling disinfecting equipment and products to building owners, manufacturers, universities and health facility owners. It also provides certificates of authorization for drones.

The firm, through its subsidiary, recently received purchase orders to supply the Fire and Emergency Management Department in Atlantic City with drone equipment. Drones are an effective tool that’ll help first responders do their work more efficiently. This contract is probably the first of many, which will help boost the firm’s sales as well as their growth.

Bantec (BANT), closed Tuesday’s trading session at $0.002, up 42.8571%, on 94,221,130 volume. The average volume for the last 3 months is 94.221M and the stock's 52-week low/high is $0.001/$0.10.

Todos Medical Ltd. (TOMDF)

QualityStocks and BUYINS.NET reported earlier on Todos Medical Ltd. (TOMDF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Todos Medical Ltd. centers on the development of blood tests for the early detection of cancer and neurodegenerative disorders, including Alzheimer's disease (AD). A clinical-stage in-vitro diagnostic company, it does so through Breakthrough Diagnostics, Inc., its joint venture (JV) with Amarantus Bioscience Holdings, Inc. Breakthrough Diagnostics is developing the Alzheimer’s blood diagnostic LymPro Test®. Todos Medical is headquartered in Rehovot, Israel.

Emerald Organic Products, Inc. (OTC: EMOR) and Todos Medical have together established Corona Diagnostics, LLC. This is a JV partnership created to address the much-needed demand for COVID-19 screening and diagnostic testing in the United States. The JV will be owned 51 percent by Emerald Organic Products and 49 percent by Todos Medical.

Todos Medical has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses). This is a method for cancer screening utilizing peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. The proprietary and patented method incorporates biochemistry, physics, and signal processing.

Todos Medical’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. The Company’s new cancer test will add a layer to currently available cancer screening and diagnostics. Todos Medical’s technology is a platform and the Company is investigating methods for using its platform on other types of cancers. Initially, the Company is concentrating on breast and colon cancers.

Todos Medical has completed the acquisition of the remaining shares in Breakthrough Diagnostics, Inc. from Amarantus Bioscience Holdings, Inc. (OTC: AMBS). Todos Medical now controls full development rights to the Alzheimer’s blood diagnostic LymPro Test™. LymPro measures cell cycle dysfunction in peripheral lymphocytes.

Todos Medical earlier entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. This is to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test.

Todos Medical has secured the rights to distribute AditxtScore™ for COVID-19 to monitor immunity against SARS-CoV-2. Blood samples will be collected by Todos and/or its network of partners. They will be sent to Aditxt’s CLIA accredited AditxtScore™ Center for processing.

Todos Medical Ltd. (TOMDF), closed Tuesday’s trading session at $0.0598, up 35.9091%, on 19,868,196 volume. The average volume for the last 3 months is 19.668M and the stock's 52-week low/high is $0.016/$0.1047.

The QualityStocks Company Corner

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Electric vehicles (“EV”) use rechargeable lithium-ion batteries rather than internal combustion engines (“ICE”) and produce zero emissions at the tailpipe, making them the perfect cars for a carbon-neutral society. With several countries across the world looking to cut their greenhouse gas emissions, EVs are poised to replace ICE cars over the next couple of decades. However, while EVs produce zero carbon emissions, sourcing the rare minerals used in EV batteries has environmental and human rights impacts. These minerals are often mined in lower-income countries without much consideration for pollution and labor rights. On top of that, EV batteries aren’t usually built with recycling in mind, and they can cause significant pollution at the end of their lives. As many more players, including Mullen Automotive Inc. (NASDAQ: MULN), enter the EV space, we are likely to see many more innovations that could boost the rate at which electric vehicle uptake occurs.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday’s trading session at $6.97, up 3.4125%, on 1,164,410 volume. The average volume for the last 3 months is 1.128M and the stock's 52-week low/high is $6.00/$19.15.

Recent News

Nemaura Medical Inc. (NASDAQ: NMRD)

The QualityStocks Daily Newsletter would like to spotlight Nemaura Medical Inc. (NASDAQ: NMRD).

  • 1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the disease
  • As many as 40% of Covid-19 related fatalities in the US also suffered from diabetes at the time of their passing
  • Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
  • In addition to sugarBEAT, its flagship device, the company also recently announced the launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores

By 2024, the International Diabetes Federation (“IDF”) predicts that the number of people with diabetes is expected to rise to 1 in 8 adults. Nearly 7 million adults have died worldwide in 2021 so far due to diabetes or its related complications – astoundingly, accounting for over 1 in 10 global deaths from any cause. While enormous, that figure does not consider the lives lost to the novel coronavirus, which has shown to be particularly deadly for people with diabetes. A study found that having Type 1 or Type 2 diabetes tripled the risk of severe illness or death from COVID-19 (https://ibn.fm/laj37). “As many as 40% of the people that have died in the US from COVID-19 had diabetes,” said Dr. Robert Gabbay, chief scientific and medical officer for the American Diabetes Association. Founded in 2011, Nemaura Medical (NASDAQ: NMRD),  a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved by creating wearable technologies and digital health care solutions that encourage and empower people to take charge of their health and well-being. Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that it has completed its initial shipment of sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its U.K. licensee, MySugarWatch Limited, previously DB Ethitronix Limited. According to the update, MySugarWatch will sell the CGM under the brand MySugarWatch(R) and has developed a subscription-based diabetes coaching and management service to be provided alongside the CGM and device sensors primarily targeting those with type 2 diabetes. “This initial shipment of sugarBEAT CGM devices to our U.K. licensee allows the company to now recognize revenue for the first time in our corporate history and is a true milestone in our development and growth,” Nemaura CEO Dr. Faz Chowdhury said in the news release. “Starting in the U.K., patients with type 2 diabetes can now benefit from a less invasive glucose monitoring option that should improve patient lifestyle, adherence and outcome. We look forward to the introduction of sugarBEAT to patients across the world, as we continue our mission of developing and introducing ground-breaking health care solutions for many of the greatest health care challenges seen across the globe.” To view the full press release, visit https://ibn.fm/crhJE

Nemaura Medical Inc. (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Its flagship product, sugarBEAT®, is a wearable, non-invasive and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and prediabetes manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading.

sugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with a smartphone app displaying glucose readings at five-minute intervals for periods of up to 24 hours. One of the great advantages of the product, apart from the fact that users no longer need to draw blood samples or prick their fingers, is that a person can wear the CGM patch on whatever day they choose. Existing CGM devices must be implanted under the skin. Wearable disposability is a unique feature of sugarBEAT and a world first, opening up vast potential for changing the way people manage their chronic disease conditions. sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union as a Class 2b Medical Device. The company submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration in 2020 which is currently under review.

Founded in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and well-being. Nemaura’s skin surface blood monitoring technology has allowed the company to create additional products, which are in the pipeline, such as Lactate Monitoring.

Technologies

Digital Solutions for Weight Loss and Potential Reversal of Type 2 Diabetes

This is a digital program that comes with more than a decade of clinical evidence demonstrating excellent efficacy. The company has combined this with its glucose-monitoring platform to bring a product to market to help people with diabetes manage their condition and potentially reverse Type 2 diabetes.

Glucose Monitoring Solutions for Diabetes Prevention and Reversal

Over 420 million people worldwide are living with diabetes, and prediabetes cases total almost three times that number. Undoubtedly, diabetes is an urgent global health crisis. Combining clinical research with patient-friendly technology, Nemaura’s sugarBEAT product delivers a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management.

Continuous Lactate Monitoring for Athletic Performance (Non-Medical)

Lactic acid is a key performance indicator for the body and a guide to how well muscles react to long term exertion and recovery. Well-trained athletes and those who regularly engage in sports are very efficient at faster lactate ‘recycling’ for extra energy (ATP). Nemaura expects to launch its lactate sensor to the sports and personal training market in 2022.

Continuous Lactate Monitoring in Disease State (Medical)

An increase in blood lactate levels is also a marker of critical disease states. Recent publications have indicated the presence of elevated lactate levels in patients with COVID-19 infection. Nemaura has developed a lactate sensor that is being integrated into the company’s platform, which will be submitted for regulatory clearance upon completion of requisite clinical studies.

Continuous Temperature Monitoring for Viral Infection Detection and Disease Progression

A person’s body temperature says a lot about their health. Several diseases, including COVID-19, are characterized by an increase in body temperature, so temperature monitoring is a vital tool in the detection, diagnosis and prevention of the spread of disease. Nemaura is expecting to submit this adaptation of the device for regulatory clearance in 2022.

Market Opportunity

Obesity and diabetes are two of the major drivers of the current chronic disease epidemic. According to the International Diabetes Federation, there are more than 463 million people living with diabetes worldwide. In the U.S., about 28,000 people are diagnosed with diabetes every week, and more than 34 million suffer from diabetes. Another 88 million Americans have prediabetes. Other industrialized countries show similar numbers based on their populations. In the U.K., 4.8 million people have diabetes, with another diagnosed every two minutes. In Germany, 9.5 million have diabetes, with almost half estimated to be undiagnosed and so at greater risk.

On average, employers and insurers spend more than $9,000 annually on health care for an employee with diabetes, compared to $1,600 annually for a healthy employee. In the U.S. alone, more than $760 billion was spent on diabetes-related health care expenditures during 2019. Nemaura is positioned at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications forecast to hit $60 billion by 2023.

Management Team

Dr. Faz Chowdhury has been CEO and chairman of the board of Nemaura Medical since 2013. He has more than 20 years of experience in the pharmaceutical and medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents and has authored textbook chapters on nano-biosciences for Wiley and Elsevier. He holds a master’s degree in microsystems and nanotechnology from Cranfield University, and a doctorate from the University of Oxford in nano-medicine and drug delivery.

Justin Mclarney is CFO at Nemaura. He most recently was the Senior Director, International Finance at Lands’ End Inc. He also worked for Office Depot as Senior Director of Finance for the largest business unit within the European group. Prior to that, he spent more than 10 years in practice, the majority of which was with Ernst & Young LLP.

Dr. Fred Schaebsdau is Vice President of Strategy & Strategic Alliances at Nemaura. He has more than 15 years of executive experience in the CGM, blood glucose monitoring and insulin delivery industries, including time with Abbott Diabetes Care, as General Manager of Dexcom Germany and at Roche Diabetes Care, where he was Senior Vice-President, Head of Global Strategy and Business Development. The firm he founded is the exclusive distributor in Europe, the Middle East and Africa of UniStrip®, the world’s first generic blood glucose test strip. He is licensed to practice medicine in the U.S. and Germany.

David Scott is Director of Commercial Development and Licensing at Nemaura. He is a trained chemist with over 35 years of experience in the pharmaceutical industry, including deal brokering, marketing, strategic planning, finance, business development and acquisitions. He has also provided licensing training for a number of multinational pharma companies and training organizations and is the author of best-selling report Scrip’s Practical Guide to Pharmaceutical Licensing.

Nemaura Medical Inc. (NASDAQ: NMRD), closed Tuesday’s trading session at $4.99, up 21.1165%, on 266,335 volume. The average volume for the last 3 months is 266,335 and the stock's 52-week low/high is $3.45/$17.40.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that it is participating in the Benzinga Global Small Cap Conference. The premier two-day virtual event is scheduled for Dec. 8–9, 2021. The company encourages shareholders and other interested parties to attend the event and learn more about investment opportunities within the global small cap space. The conference is designed to bridges the gap between small cap companies, investors and traders. The event provides an ideal environment to learn about small cap investing. The conference agenda features insightful educational modules and provides a clear look at a curated group of small cap investment opportunities. In addition, the event provides opportunities to interact with the global small cap audience in an intimate, virtual setting. To view the full event, visit https://ibn.fm/hUAjk. To view the full press release, visit https://ibn.fm/9SzAE. Lexaria Bioscience (NASDAQ: LEXX, LEXXW) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve delivery of lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (“APIs”) into the bloodstream while speeding onset, increasing bioavailability and improving efficacy. For more information, visit the company’s website at www.LexariaBioscience.com. To learn more about Benzinga’s Small Cap Conference, visit: https://ibn.fm/BenzingaSmallCapDec2021

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday’s trading session at $4.92, up 4.2373%, on 36,915 volume. The average volume for the last 3 months is 36,915 and the stock's 52-week low/high is $3.9751/$12.50.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

A new study has found that the rate of survival for young individuals diagnosed with central nervous system (“CNS”) tumors is higher the farther they live from healthcare facilities. Associate professor at the Brown School at Washington University Kimberly Johnson reported  that one of the possible causes for this was that patients who suffered from noncentral nervous system cancers likely lived further away from healthcare facilities, which increased the likelihood that they were diagnosed when their tumors were more difficult to treat and in advanced stages. In addition, patients with CNS tumors may have to travel farther for care in order to access facilities with more experience treating these tumor types. Aggressive forms of brain cancer could soon come to face-to-face with novel and efficacious formulations that companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are seeking to develop in order to address the unmet clinical needs of patients.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday’s trading session at $0.9922, up 5.5532%, on 199,158 volume. The average volume for the last 3 months is 199,158 and the stock's 52-week low/high is $0.89/$4.46.

Recent News

Green Hygienics Holdings Inc. (OTCQB: GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (OTCQB: GRYN).

Green Hygienics Holdings (OTCQB: GRYN) today provided an update on the 2021 harvest and current business development activities. According to the update, Green Hygienics has been focused on advancing several main areas of business development over the last quarter. These include its aggressive growth strategy where, to date, the company has financed its operations almost entirely through direct investment from management, and further shares have been issued instead of cash to ensure management is vested. The result is that Green Hygienics, unlike most companies in the sector, has very few shares outstanding, less than 45M fully diluted. In addition, the company announced its plans to pursue strategic acquisitions at a discount to market. As part of this effort, Green Hygienics is targeting acquisitions that are already cash flowing and have one or more aligned, established brands that the company can add supply chain or other value to. Further, in the last 24 months Green Hygienics has demonstrated its ability to cultivate premium quality hemp cost effectively and with the extraordinary potential to scale. This year’s harvest was double that of last year and will continue to grow with increasing demand as the company secures sales and distribution channels. The update also discussed the company’s engagement of a new external accounting firm from San Diego, AWICPA. The firm will manage payroll, develop policies, procedures and internal controls to manage inventory and accounts payable as well as adjust records to reflect Generally Accepted Accounting Principles (“GAAP”). Finally, in addition to the potential for revenue growth a material financing or acquisition may provide, Green Hygienics intends to launch four e-commerce websites in the first two quarters of 2022 to generate critical cash flow. To view the full press release, visit https://ibn.fm/LZdjI

Green Hygienics Holdings Inc. (OTCQB: GRYN) is a California-based innovative technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids.

The company aims to be a leader in compliance and capabilities in the hemp and cannabinoid supply marketplace. By leveraging state of the art technologies, the company intends to open up a whole new world of novel cannabinoids and targeted bio-delivery technologies never before explored, solving the issues of stability, pharmacokinetics, biological tissue penetration and bioavailability.

Dedicated to creating the hemp industry’s safest and finest quality products, the company will be uniquely positioned to deliver product efficacy and supply chain solutions to consumers, as well as to leverage these within its own products and brand portfolio.

USDA Organic Certification and FDA Registration

On August 26, 2020, Green Hygienics registered with the U.S. Food and Drug Administration pursuant to the Federal Food Drug and Cosmetic Act, as amended by the Bioterrorism Act of 2002. This registration strengthens the company’s core mission to provide product efficacy to the pharmaceutical industry and consumers alike.

On September 30, 2020, Green Hygienics was granted USDA Organic Certification (7 CFR Part 205) for the cultivation and post-harvest processing of industrial hemp by the California Certified Organic Farmers for its Sol Valley Ranch property. This certification further enables the company to supply certified organic hemp products to national and international markets.

Market Opportunity

Green Hygienics is focused on finding, acquiring and developing strategically positioned businesses, as well as the best innovations within the hemp industry – a fast-progressing market with remarkable opportunities for growth. The industrial hemp market is expected to reach $5.33 billion in 2020 and is projected to rise to $15.26 billion by 2027, achieving a CAGR of 15.8%, per Grand View Research.

Capital Structure

GRYN has less than 42 million shares outstanding, fully diluted. The company has just 7.2 million common shares in float and boasts a balance sheet with no toxic debt or overhang.

Key Management

Dr. Levan Darjania serves as the company’s Chief Science Officer. Darjania has over 26 years of experience in biotechnology and pharmaceutical drug development. His research and development experience has led him to develop many in-house and collaborative R&D programs over the course of his career.

Kyle MacKinnon serves as GRYN’s Chief Operating Officer. He has extensive knowledge in cannabis processing and was previously the Business Development Manager of Advanced Extraction Systems Inc., a leader in CO2 Supercritical Fluid Extraction. MacKinnon brings over 20 years of sales and management experience to the company.

Ronald Loudoun is the President, CEO, Secretary and Director of Green Hygienics. He received an undergraduate business degree from the British Columbia Institute of Technology. Before joining Green Hygienics, he was the founder and a director of renewable energy firm Archer CleanTech Inc.

Jerry Halamuda is the Senior Vice President of Business Development of the company’s Agriculture Division. He has an extensive career working in the agriculture and horticulture industry. Halamuda has founded, managed and operated multiple successful companies, including Color Spot Nurseries.

John Gildea is GRYN’s Senior Vice President of Corporate Development. He has over 20 years of experience working within the private and public markets. His expertise includes negotiating and structuring private and public financing and mergers. During the course of his work, Gildea has established trusted relationships with a network of equity and capital partners.

 

Green Hygienics Holdings Inc. (OTCQB: GRYN), closed Tuesday’s trading session at $0.7001, up 0.4448%, on 56,285 volume. The average volume for the last 3 months is 56,285 and the stock's 52-week low/high is $0.601/$2.45.

Recent News

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF)

The QualityStocks Daily Newsletter would like to spotlight Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF).

  • PLGNF adds three iGaming operators to platform, additional eight at testing and integration stages
  • Growth indicators from November include 12% player wager increase, 28% active player growth, 22% increase in bet spots
  • PLGNF’s proprietary technology enables seamless integration at operator level, allows user access without sharing sensitive data or requiring app store download.
  • PLGNF has a typical SaaS business model which includes zero player acquisition cost.
  • Grandview Research forecasts global online gambling market to reach $127.3 billion by 2027, CAGR of 11.5% from 2020 to 2027

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF), a propriety SaaS technology company delivering live dealer mobile technology to global online gaming operators, recently announced the addition of three new operators to its platform, bringing the total to 26. The company also reported that critical key performance indicators were up for November, including 12% growth in player wagering, a 28% increase in monthly active player numbers, and 22% growth in bet spots (https://ibn.fm/iw6zA).

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) is a SaaS technology company focused on developing and licensing digital content for the growing global iGaming market. The company provides a multi-tenant gateway that allows online operators the ability to offer their customers innovative iGaming software solutions. Its current software platform includes Live Dealer Casino, E-Table Games and Daily Fantasy Sports. Seamless integration at the operator level allows customer access without requiring the sharing of any sensitive customer data. Playgon games run on any browser and any device as fast and secure as a native app, without requiring any app store download. All that’s needed is a stable internet connection. The gaming experience is identical across all mobile devices. As a true business-to-business digital content provider, the company’s products are scalable turnkey solutions for online casinos, sportsbook operators, location-based operators, media groups, and big database companies.

Playgon’s proprietary technology provides digital games for online gambling sites and mobile device apps, with the company licensing its mobile live-dealer technology to online gaming operators worldwide. Playgon combines high definition live streaming dealers with state-of-the-art augmented reality betting to provide the most authentic casino experience, live from Las Vegas. Playgon’s mobile platform features popular table games, all optimized for one-handed play on mobile devices.

The COVID-19 pandemic has accelerated an already existing shift away from location-based casinos to online gambling. At the same time, the proliferation of mobile devices has provided players with new access to betting. A younger, tech-savvy consumer demographic is driving adoption of digital gaming globally. To meet this demand, Playgon has launched a studio with 10 gaming tables from which its live dealer streaming video originates. The company’s platform is live with multiple online casino operators through four aggregator clients in South Africa and Europe, and commitments are coming in from more.

Playgon plans to expand the studio to 25 tables in the near term and is working to establish a U.S. strategy. The company will continue to expand licensing of its live dealer games to iGaming operators worldwide under a SaaS license agreement. As a B2B software supplier, Playgon avoids player acquisition costs.

Games

Live Dealer Casino

Playgon offers the first and only Live Dealer Casino streaming live from Las Vegas. The company brings cutting-edge handheld features and functionality to the mobile generation of gaming enthusiasts who demand a world-class gaming experience on all devices. Playgon’s Blackjack delivers the look and feel of location-based casino tables with features providing players with the most unique user experience. The company’s true-to-life Roulette offers players a clear and uninterrupted view of the dealer, wheel, ball, bets, results, trends and statistics. Players can strategize, place multiple bets, track results and review trends without ever losing focus of the game.

Playgon’s traditional Baccarat and proprietary Tiger Bonus Baccarat™ prove their worth by not only recognizing the need for a prominent product, but by adding elements which separate them from the pack without removing their authenticity. The games mix advances in technology with the traditional game attributes that have resonated and captivated players for hundreds of years.

eTable Games

To lead the rise of mobile-first gaming, Playgon developed a user experience perfected for one-handed play. Providing this next evolution in gaming technology ensures the company’s client operators loyalty from existing customers and is a powerful strategy to attract and retain new players. Playgon’s VEGAS LOUNGE™ brings together an innovative mix of games, technology and gameplay that offers players an authentic experience and real Las Vegas casino fun every time, everywhere.

Daily Fantasy Sports

Playgon’s Daily Fantasy Sports (DFS) are a subset of fantasy sport games which typically target a younger demographic. DFS provides iGaming operators a turnkey fantasy sports platform that can quickly go to market, integrate with the operator’s existing operations and services, and be customized to match and enhance the operator’s brand. The platform is mobile and desktop friendly, built for regulated market environments, and allows operators to monetize users through a network of shared liquidity.

Market Outlook

Online casinos and sports betting sites/apps are increasingly adding market share to traditional location-based casinos. This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, as well as tech like digital wallets and digital gameplay that underpins Playgon Games. The company has been described as “Netflix + Vegas, all in one.”

The online gambling market is slated to reach a value of $127.3 billion by 2027, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25 percent year over year. The current global online Live Casino TAM is estimated at about $6 billion annually, and revenue is forecast to reach more than $8 billion by 2023 and more than $13 billion by 2027.

Management Team

Darcy Krogh is CEO of Playgon Games. He is a veteran of the iGaming industry with over 20 years of experience. In 1999, he co-founded Chartwell Technology Inc., which pioneered the development of browser-based digital content for the iGaming industry. After that company was sold to Amaya Gaming Group, he served as VP Business Development with Amaya. In 2016, he started Playgon Games (formally Global Daily Fantasy Sports Inc.) as President and CEO. His experience in the online gaming industry includes sales and marketing, relationship management, corporate finance, M&A, and strategic corporate development.

Guido Ganschow is President of Playgon Interactive. He has more than 12 years of experience in creating real-time Live Dealer technology and platforms and was the co-founder and Creative Director for a Macau-based casino consortium. Between 2008 and 2014, he successfully created and established Live Dealer platform businesses in Asia and Europe, and executed commercial partnerships, sales, and integration of the Live Dealer solution with major global gaming brands, including Ho Gaming Group, Chartwell Technology and Amaya Gaming Group.

Steve Baker is COO of Playgon. He is a former VP Operations for Shaw Communications, where he was directly involved in video streaming, home entertainment, new products, sales and M&A. He oversaw revenue growth from $300 million to $2.8 billion and employee growth from 350 to 13,000. He has broad experience and a proven record in development and implementation of cost effective and efficient growth strategies transitioning businesses from development to operations.

Harry Nijjar is CFO of Playgon Games. He is currently a Managing Director with Malaspina Consultants Inc. and provides CFO and strategic financial advisory services to his clients across many industries. This experience has allowed him to help his clients successfully navigate the regulatory and financial environments within which they operate. Mr. Nijjar holds a CPA-CMA designation from the Chartered Professional Accountants of British Columbia.

Playgon Games Inc. (PLGNF), closed Tuesday’s trading session at $0.269, up 2.2231%, on 20,877 volume. The average volume for the last 3 months is 20,877 and the stock's 52-week low/high is $0.197/$0.6282.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

  • Canadian-based clean energy solutions innovator FuelPositive Corp. is focused on developing green ammonia as a more efficient and sustainable source of fuel than the popular fossil fuel alternative hydrogen
  • FuelPositive’s Hydrogen-Ammonia Synthesizer technology provides the means of storing hydrogen as green ammonia for effective transportation and storage, with the option of easy conversion back to hydrogen for use in hydrogen fuel cells and other pure hydrogen applications
  • The company is among a handful of entities that have noted Canada’s outsized support for fossil fuels recently, and plans to roll out its IP next year in “real world” demonstration pilot projects
  • Carbon footprint reduction has gained global attention in recent years amid concerns about climate change resulting from pollutants, and policy representatives from around the world recently gathered in Scotland for the COP26 2021 United Nations Climate Change Conference to address related issues

When green energy innovator FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) commissioned an analysis of Canada’s green off-peak electricity capacity earlier this year to help measure the fuel needs and carbon emissions of the country’s transportation sector, FuelPositive was adding its own insights to a recent series of examinations of Canada’s renewable energy performance.

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Tuesday’s trading session at $0.154, up 4.6907%, on 264,963 volume. The average volume for the last 3 months is 264,963 and the stock's 52-week low/high is $0.03224/$0.326.

Recent News

RYAH Group Inc. (CSE: RYAH)

The QualityStocks Daily Newsletter would like to spotlight RYAH Group Inc. (CSE: RYAH).

  • Multiple ongoing studies are researching the relationship between medical cannabis and cancer treatment
  • The viability of clinical studies within the sector is hampered by lack of exact measurement of a patient’s intake
  • RYAH Group intends to resolve this issue with the launch of it’s proprietary RYAH Smart Dry Herb Inhaler
  • The company successfully delivered on its first Inhaler order in May 2021, and announced that they had received a follow-on order in November 2021

In 1980, The United States National Cancer Institute (“NCI”) began experimental distribution of a novel drug called Marinol, an oral form of THC (the primary active ingredient in cannabis), to cancer patients in San Francisco (https://ibn.fm/HE5vn). Just over a decade later, the city of San Francisco celebrated the passing of Proposition P in 1991, a revolutionary bill that legalized the use of medical cannabis within the city limits. There’s an abundance of evidence supporting the use of medical cannabis to treat cancer symptoms. Now, rather than just treating symptoms, science has begun to ask, “could cannabis be used to treat cancer itself”?  A recognized leader in volume management technology for plant-based medicine, RYAH Group (CSE: RYAH) is in the middle of the action. RYAH develops innovative IoT products that capture powerful data insights and is on a mission to to transform patient care using big data and AI to reshape understanding and uses of plant-based medicines. The company’s robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which then helps doctors and patients personalize plant-based treatments to better predict treatment outcomes. Little wonder that RYAH devices and data are being used by a rapidly growing number of participants in plant-based clinical trials around the world. The state-legal cannabis industry is in a precarious position. With that in mind, the Centers for Disease Control and Prevention (“CDC”) has offered guidance on how businesses can develop cannabis policies that adhere to state regulations but reduce the risk of impaired driving. While federal law still classifies cannabis as a Schedule I substance with no accepted medical use and a high potential for abuse, 36 states have legalized medical cannabis and 19 states allow recreational use. On top of that, there is still no accurate way to test for THC. The level of THC in the bloodstream doesn’t always correspond with the level of impairment; tests have found that THC can stay for up to 90 days in the body. For employees who consume marijuana, especially those who operate vehicles for a living, this can have significant consequences. The step taken by the CDC to provide marijuana policy guidance to employers is one more step to making it easier for patients who need medical marijuana to use it without fear of putting their jobs at risk. In addition, the existence of IoT marijuana-dosing devices, such as those produced by RYAH Group Inc. (CSE: RYAH), eases the task of adhering to the dosage instructions recommended by professionals.

RYAH Group Inc. (CSE: RYAH) is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and university research centers, for experimentation and treatment validation – significantly reducing variations in patient-related trials. RYAH unlocks data in the complete therapeutic plant lifecycle – from seed to consumption.

Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union, as well. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis.

Product Portfolio

The company’s current portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component and the mobile application. The product line currently includes a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.

RYAH Smart-Inhaler

The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and dosages, all of which can be customized to individual needs and doctor recommendations, as well as a post-session review mechanism that allows the collection of session data and feedback for further efficacy analysis for customized dosing capabilities.

RYAH’s proprietary stainless-steel cartridges for the inhaler use QR technology that contains lab testing and grower information pertaining to the specific strain, thereby mitigating elicit product use and enabling completely transparent remote medicinal analytics, from seed to consumption.

In addition, the RYAH Cartridges provide a unique closed-loop recurring revenue opportunity for the company, as the RYAH Inhaler only works with this type of proprietary cartridges that licensed partners fill with medicine. The partners benefit from all the back-end data, providing them access to consumption habits, statistics and other data on patient preferences.

RYAH Smart-Patch

The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and the heating element is completely IoT and controlled by RYAH’s proprietary smartphone applications, which allows scheduling and ‘boosting’ medicine release, on-demand.

RYAH Smart-Pen

The RYAH Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect’, enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. The Smart-Pen will feature cartridges that contain CBD, THC and other isolates such as flavonoids or vitamins, or other solutions. There is a built-in mechanism designed to control usage based on recommended dosing schedules.

RYAH MD

RYAH MD serves as a remote and interactive patient-doctor collaboration and dosing administration platform. Doctors can remotely set dosage amounts for their patients, creating digital prescriptions for the RYAH IoT devices and tracking patient usage in real-time. RYAH MD offers features that include real-time monitoring, appointment booking, doctor-patient video calls and science-based strain recommendations, as well as promoting a better understanding of the effects and benefits of those recommendations among patients. Information is gathered from all of the RYAH devices.

PotBot App

The PotBot App is a medical cannabis education mobile application that leverages patented AI technology to capture structured and unstructured data to assist patients in learning about various treatments in plant-medicine based on their efficacy goals. The PotBot App is currently one of the top-rated medical cannabis educational mobile applications on the Apple App Store in the United States, with over 300,000 downloads.

Through the combination of peer-reviewed and empirical data, the PotBot App provides detailed information on the targeted and tested cannabinoid levels and associated strains from cannabis patients. The result is personalized and driven by data to inform patients of potential product matches associated with similar ailments and efficacy goals.

Market Outlook

RYAH holds a unique position in the $100.3 billion medical plant market, with the potential to capture and capitalize on growth opportunities made available by both the IoT and Data Intelligence sectors.

In 2018, the global IoT market was valued at $212.1 billion, and it is expected to grow exponentially to $1.3 trillion by 2026, registering a CAGR of 25.68%, according to Verified Market Research (https://ibn.fm/XtkPZ).

Management Team

Dr. Boris Goldstein, Ph.D., is the founder and Chairman of RYAH Group. He is a seasoned entrepreneur, investment banker and venture capitalist. He started his career as the founder of Software House HT, which grew into a worldwide corporation with over 40 offices in 17 countries. Since then, Goldstein has founded and served on the boards of directors and advisory boards for numerous companies in Silicon Valley and Silicon Alley. Goldstein brings experience in fundamental research, investment and technology, authoring multiple patents and books.

Gregory Wagner, MBA, is Chief Executive Officer and Director of RYAH Group. He has over 20 years of experience in global financial markets and entrepreneurship. Wagner has held executive roles in the United States and London. He has co-founded and built several startups from the ground up. His current licensures and degrees include FINRA Series 7, 63, 24 and 55, as well as an MBA from Fordham University. Wagner received a Certification in Innovation and Strategy from Harvard University.

RYAH Group Inc. (CSE: RYAH), closed Tuesday’s trading session at $0.05, up 11.1111%, on 90,400 volume. The average volume for the last 3 months is 712,235 and the stock's 52-week low/high is $0.04/$0.20.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

Friendable (OTC: FDBL), a mobile technology and marketing company, today announced that its CEO Robert A. Rositano Jr. is featured in a one-on-one interview with the Hellblazerbiz Podcast. The engaging conversation brings to light the difficulties and setbacks independent artists face when it comes to revenue and recognition during a time when a worldwide pandemic continues to challenge in-person experiences. Now, Fan Pass Live makes it easier for artists to connect with their fans, providing artists more freedom and control over the content they create and share, from the distribution of their music to merchandise and exclusive content, the ability to obtain production equipment for shows, and more. “We are really pushing the boundary on the freedom for artists to control their music,” said Rositano Jr. “We also nurture their careers by helping find the right equipment and more. Fan Pass is a one-stop shop, where artists can create events and have fans access the backstage, as it were, allowing them to participate in an event no matter where they are in the world. Stay tuned as we are in the final stages of finalizing independent music distribution services, play listing and other services that will truly elevate the game of all our indie artists’ ability to succeed.” To view the full press release, visit https://ibn.fm/i8e53

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Tuesday’s trading session at $0.0043, up 34.375%, on 14,599,719 volume. The average volume for the last 3 months is 14.6M and the stock's 52-week low/high is $0.0028/$0.0979.

Recent News

Tingo Inc. (OTCQB: IWBB)

The QualityStocks Daily Newsletter would like to spotlight Tingo Inc. (IWBB).

Tingo (OTCQB: IWBB), the leading agri-fintech in Africa, has partnered with Visa Inc. The partnership is intended to expand the company’s footprint across Africa as well as augment its business offerings across Nigeria by increasing financial services on Tingo’s platforms and driving their greater adoption, particularly digital payments. “With a shared vision to enable individuals, businesses and economies to thrive through financial services, Visa is expected to be a powerful lever to drive Tingo’s expansion across the African continent and beyond.,” a recent article reads. “But the partnership will not stop there. Committed to financial education, Tingo aims to increase financial literacy and greater economic independence across the continent, for which alliance with Visa will be crucial. Tingo and Visa will join forces to deliver knowledge and learning tools to empower communities with adequate information so that they can fully leverage the benefits of increased access to financial services.” To view the full article, visit https://ccw.fm/DoXBD

Tingo Inc. (OTCQB: IWBB) is a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa. The company aims to be Africa’s leading agri-fintech player, transforming rural farming communities to connect through its proprietary platform to meet their complete needs – from inputs and agronomy to off take and marketplace – and deliver sustainable income in an impactful way. The company’s vision is to build complete digitally inclusive ecosystems that promote financial inclusion and deliver disruptive micro-finance solutions, empower societies, produce social upliftment in rural communities and open international opportunities.

Tingo believes that a truly connected world will help contribute to a better global society. The company’s core focus areas are telecoms, financial services/fintech and agritech. Tingo’s goal is to provide a best-in-class customer experience, support the domestic economies of its host countries and support technological and financial inclusion to end the poverty premium. Through this, Tingo hopes to deliver attractive returns to shareholders while investing in the long-term future of the company and its subsidiaries.

Global climate change is challenging sustainable production and food security. Tingo’s strategy and market execution provide an opportunity for Africa to be a core focal point to solve a number of key areas of concern, including food security, gender equality, financial inclusion and poverty alleviation, to name a few. Disruption of micro finance through the use of DeFi-based stable coins and smart contracts will give agri-communities access to capital markets-driven digital finance solutions that make them more competitive and sustainable economically, striking a good balance of returns between digital asset providers and Tingo as the service partner. This innovation will deliver significant access to much needed finance at ‘Grassroot’ levels, delivering tangible social upliftment and GDP growth in the African markets served by Tingo.

Tingo Mobile, with more than nine million subscribers, is Nigeria’s leading technology and device-as-a-service platform aimed at accelerating digital commerce, especially in the country’s agritech and fintech verticals. The company helps farmers acquire mobile phones through a unique leasing plan, connecting them to mobile and data networks through its own virtual mobile network. Tingo also connects farmers to markets, services and resources via Nwassa, its digital agritech marketplace platform that commenced operations in 2020. The company has also launched a beta version of TingoPay – a B2B and B2C fintech app aimed at providing financial services to users inside and outside of the agriculture value chain. Among the services offered are mobile wallets, payment processing and access to specialist lenders, insurers and pension products.

Tingo will soon announce its innovative blockchain-based solution for use of digital stable coins to empower frictionless trade across borders in Africa. The company’s market-proven model in Nigeria is its core foundation, enabling Tingo to deliver the same service model across Africa to become the continent’s leading agri-fintech business powered through smartphone technology.

The African Continental Free Trade (ACFT) plan will be a key framework to prepare the company to be the leading intra-Africa trading hub for trade flows across Africa in the medium term, when it is likely the agreement will be executed into tangible activity. Tingo is well positioned to easily transform the goals of the ACFT into reality when finally implemented by the African Union and the various African countries that have not signed up.

Tingo posted total revenue of $594 million in 2020, with $212 million EBITDA. As of December 31, 2020, Tingo has 9,344,000 subscribers. The company is confident that these figures will grow through its expansion across Africa and natural progression of business in Nigeria.

Businesses

Tingo has four core businesses:

  • Mobile Phone Leasing – Tingo has distributed almost 30 million mobile handsets since 2014 and will continue to replace the devices of its installed customer base every three years. Tingo Mobile provides the latest mobile phone handsets at an affordable price point and allows customers to spread payments over 36 months.
  • Mobile Voice and Data Service – Through a mobile virtual network, Tingo provides its customers with voice and data services, allowing customers to communicate effectively, both inside and outside the agricultural ecosystem.
  • Nwassa Marketplace Platform – Nwassa is Tingo’s proprietary agritech platform which provides Africa’s farmers with access to global markets to secure more competitive pricing for their crops. The platform processes 500,000 daily transactions with a value of over $8 million. A select group of trusted partners can assist smallholder farmers and agricultural cooperatives with packaging, warehousing, and dry and wet cargo logistics, as well as up-to-date information from the global agricultural sector. Tingo provides its customers with digital wallet services, which enable them to send and receive domestic payments, monitor cash flow in real time and securely hold money. The company also provides access to other services, such as utility bill payment, virtual airtime top-up, insurance services and alternative lending solutions.
  • TingoPay – Since the launch of the Nwassa platform, Tingo has been a dominant player in the B2B fintech vertical. After many successful months of operating Nwassa, Tingo entered the fintech B2C vertical to extend its B2B offering to a broader market beyond agriculture.

TingoPay is still in its beta phase and will launch in 2021 with a comprehensive marketing campaign. TingoPay offers the following services:

  • Tingo Wallet top-up
  • Peer to Peer payments, inclusive of merchant payments at the stores
  • Utility payments – airtime, broadband, cable, electricity, water, hotel, flights etc.
  • Pension payments
  • QR code payment services

Market Opportunity

Africa is the second-largest continent by population. It is also the youngest by far, with a median age of 18 for its 1.3 billion people. Tingo believes the building blocks for growth in Africa’s agriculture industry are in place and that the company is well positioned to participate in the upside. Sub-Saharan Africa’s population is growing at a rate of 2.7 percent per year. At the current growth rate, the continent’s population will double by 2050. Africa’s youthfulness represents a significant opportunity for material growth in demand for agricultural commodities. This younger generation is also being born into a digital world and is comfortable using technology.

Africa’s governments are improving business conditions for entrepreneurs and small businesses. Sub-Saharan Africa’s World Bank Doing Business rank has improved from 45 in 2004 to 65 in 2020. Tingo believes this trend will continue and encourage establishment of more new ventures across all economic sectors, including agriculture.

Africa attracted $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018. Investments are increasingly focused on services and industrial sectors. Only 20 percent of investments are in extractive industries – a clear reversal from 2008, when 55 percent of FDI was aimed at resource extraction. Tingo believes FDI into Africa will help resolve significant infrastructure constraints and create value for agribusiness.

Management Team

Dozy Mmobuosi is the CEO of Tingo. He cofounded Tingo Mobile PLC (Nigeria) in 2001 and led the design and launch of Nigeria’s first SMS banking solution, which is still in use in the country today. He also headed a team of more than 120 Chinese and Nigerian engineers in the construction of two mobile phone assembly plants in Nigeria, which have produced and distributed 20 million phones across the country. He has led Tingo’s growth to more than $600 million in revenue annually. He holds a Ph.D. in Rural Advancement from UPM Malaysia.

Dakshesh Patel is the CFO of Tingo. He was formerly CFO of NatWest’s Global Debt and Investment Banking division. He has served as a Director at Gerken Capital Associates, a San Francisco-based alternative asset fund manager. He also led the restructure of Lloyds Banking Group (last financial crisis); managed integration of two leading shipping groups’ global treasury function to create world-leading shipping group Maersk Shipping; built three fintech companies; and exited one to Worldpay. Mr. Patel has strong banking experience, with a focus on Africa. He is a chartered accountant.

Chris Cleverly is president of Tingo. He has served as CEO of the Made in Africa Foundation, and as CEO of blockchain payments gateway startup Kamari. He has been a board member of several companies, both public and private, in the UK, India, China and Africa. He has advised multiple UK companies on their entrance into African markets, and regularly advises the UK Government on development issues and African governments on investment issues.

Clarence Simms is the Chief Technology Officer at Tingo. He has 25 years of IT and IT management experience. He has worked in IT Shared Services Technical Operations and IT Program Management for Huawei Technologies and MTN. As an entrepreneur, he created Africaprepay.com, a service that allows African Diaspora travelers to send airtime, pay bills, send mobile money and transfer money to a bank account from anyplace in the world.

Rory Bowen is the Chief of Staff at Tingo. Mr. Bowen started his career in traditional capital and derivatives markets working for Moneycorp and Tradition UK in European and emerging markets across FX, interest rate derivative and government bond markets. He has also spent time with one of Europe’s fastest growing fintech’s banking circles. Before joining Tingo, he was Chief of Staff at FinTech Alliance, an organization established in partnership with the UK Government Department for International Trade to foster innovation, growth and foreign direct investment (FDI) in the financial services sector and facilitate greater public/private cooperation.

Tingo Inc. (OTCQB: IWBB), closed Tuesday’s trading session at $4.32, even for the day, on 100 volume. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $1.01/$8.98.

Recent News

Save Foods Inc. (NASDAQ: SVFD)

The QualityStocks Daily Newsletter would like to spotlight Save Foods Inc. (NASDAQ: SVFD).

Save Foods (NASDAQ: SVFD), an agri-food-tech company focused on developing and selling eco-friendly products specifically designed to extend the shelf life and ensure food safety of fresh fruits and vegetables, has completed the first commercial sale of its treatment for Medjool dates in the Arava region in Israel, which is the largest exporter of Medjool dates in the world. The sale was completed with Galilee Export, the second largest exporter of fresh produce in the country. This sale comes on the heels of an earlier announcement regarding the company’s first sales in the same region of its treatment for bell peppers. According to the announcement, Galilee Exports will begin broad-scale commercial treatment of its Medjool dates during the upcoming season. Growing and harvesting Medjool dates is more labor intensive than other produce because cannot be picked until they ripen on the trees; other dates ripen after harvesting. Therefore, the cost of harvesting Medjool dates is higher, and Save Foods treatments allow Galilee Exports to maximize the revenues of each harvest, while providing consumers with the highest-quality product, said a Galilee Exports representative. “The benefits of Save Foods’ treatment are recognized on a continuously growing number of produce, Medjool dates being one of them,” said Save Foods CEO Dan Sztybel in the press release. “Our relationship with Galilee Export represents a significant opportunity for the company beyond dates; they have a well-established and growing presence in the global produce market, and a reputation for high-quality produce. I am confident that we will continue to expand our partnership to include new crops and exposure to new markets going forward.” To view the full press release, visit https://ibn.fm/Zix3U

Save Foods Inc. (NASDAQ: SVFD) is an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables. The company is focused on addressing two of the most significant challenges faced by the industry: (1) food waste and loss, and (2) food safety.

Fungi like mold and yeast, as well as foodborne pathogens, are typically responsible for fresh produce spoilage and foodborne illness. Save Foods’ integrated solutions improve safety, freshness and quality every step of the way, from field to fork. The company’s natural products control human and plant pathogens, allowing growers, packers and food retailers to reduce waste and boost revenues. More food ends up on consumers’ plates, and less ends up in landfills.

Save Foods’ products use all-natural ingredients to protect fresh produce from microbial spoilage and pathogens with zero toxicity. The company’s treatments leave no harmful residues on produce or in the environment and maintain product freshness over time. Fresh produce treated with Save Foods’ products can already be found in supermarket chains across the U.S. and Europe. Those chains have reported that the company’s products are reducing fruit spoilage by 50% on average at the retail level. With no need for additional steps in the treatment process nor special equipment, Save Foods’ products are easy to implement and come in versatile applications suitable for the different stakeholders along the food supply chain.

Initial applications for the company’s offerings include post-harvest treatments in fruit and vegetable packing houses that process citrus, avocados, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of chemicals and their residues, Save Foods’ products not only prolong shelf life; they also ensure safe, natural and healthy food. Save Foods has the first green products that could realistically replace the different chemicals used today in food treatment while controlling waste and food safety.

Products & Technology

  • SavePROTECT or PeroStar, a processing aid added to fruit and vegetable wash water and used in post-harvest treatment;
  • SF3HS and SF3H, post-harvest treartment solutions to control both plant and foodborne pathogens;
  • SpuDefender, for controlling post-harvest potato sprouts; and
  • FreshPROTECT, for controlling spoilage microorganisms on post-harvest citrus.

Save Foods’ products are based on a proprietary blend of food acids which have a synergistic effect when combined with certain types of sanitizers and fungicides at low concentrations in a non-organic setting. The combination eliminates fungicide residues or reduces them to levels below the established Maximum Residue Levels (MRLs). The company’s fruit and vegetable wash is odorless and does not irritate human eyes, skin or airways. Save Foods’ blend does not leave any residues of toxicological concern on the treated surface of produce, and all its ingredients are classified by the U.S. Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS). There are 7 patent families related to Save Foods’ technology.

Applications

The company’s products have been commercially validated on citrus, mangos, avocados, pears, bell peppers, microgreens and various fresh cut vegetables. Save Foods is in the validation process for bananas, apples, figs, berries, lettuce, papayas and more. The company is also validating the efficacy of its products for pre-harvest treatment, starting with citrus trees.

Market Outlook

The world population is expected to grow to almost 10 billion by 2050, boosting current agricultural demand by some 50%. Providing healthy and safe food for the world’s population is one of the biggest challenges of the 21st century.

Globally, around 664 million tons of fresh fruits and vegetables are lost every year from field to fork, wasted by spoilage, and almost one in 10 people globally falls ill every year from eating contaminated food, with an estimated resulting cost around $90 billion.

Disposing of all that wasted food requires additional expense and harms the environment with resulting greenhouse gas emissions. The post-harvest food treatment market was valued at $1.5 billion in 2019 and is expected to grow to $2.3 billion by 2026, achieving a CAGR of 6.5%.

Management Team

David Palach is CEO of Save Foods. He spent over a decade with Intel Israel, where his last position was Manager of Business Development for Israel and Europe. Prior to that, he served as a controller of two of Intel’s largest factories in Israel, where he supervised a budget of over $1 billion. He also served as the CEO of B-Pure Corporation Ltd., a management and maintenance company involved in protecting and improving the environment. During his tenure, he helped turn around several struggling subsidiaries and made them profitable.

Vered Raz Avayo is the company’s CFO. Before joining SaveFoods in 2018, she spent more than 10 years as CFO at LGC, the Leviev Group of Companies. She has operated her own financial and business consultancy and has served as a director for a number of public companies in Israel.

Dan Sztybel is CEO of SaveFoods Ltd., the Israeli subsidiary of Save Foods Inc. He previously led the Life Sciences Advisory at EY Israel and early on recognized the potential of Israel as a center of innovation in the digital health space. He has been an adviser on digital health strategy to large pharmaceutical companies and is a cofounder of MyndYou, a digital health start-up focusing on cognitive impairment. He is also a co-founder of the DigitalHealth.il conference, the largest digital health conference in Israel.

Dr. Neta Matis is Vice President of R&D at Save Foods Ltd the Israeli subsidiary of Save Foods Inc . She holds a Ph.D. in organic chemistry and an MBA from Tel Aviv University. Prior to joining Save Foods in 2019, she held multiple research chemist and product development roles at Verdia Inc. and its parent company, Helsinki-based Stora Enso Oyj.

Nimrod Ben Yehuda is the founder and CTO of Save Foods Ltd. He was previously the CEO/CTO of Swissteril Water Purifications Ltd. He has also been CEO at Nir Ecology Ltd., and was Joint-CEO at NitroJet Ltd.

Dr. Art Dawson is the U.S. Business Manager for SaveFoods Inc. He has been president of The Dawson Company, which focuses on creating sales opportunities for new agricultural technologies, previously Dr. Dawson held senior industry positions like General Manager Worldwide of the Decco , the Post Harvest Division for Elf Atochem. He holds a Ph.D. in Plant Physiology from UC Riverside and is licensed in California as an agricultural Pest Control Advisor.

Save Foods Inc. (SVFD), closed Tuesday’s trading session at $4.98, off by 14.726%, on 118,097 volume. The average volume for the last 3 months is 118,097 and the stock's 52-week low/high is $4.6506/$30.10.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) has officially entered the second phase of a three-phase development strategy that captures its expansion plan in Florida after installing, commissioning and loading five of 30 planned modular grow pods, which are already growing plants. RWB, through its subsidiary Red White & Bloom Florida LLC (“RWBFL”), is fast-tracking the remaining 25 pods. Collectively, the 30 pods will provide about 19,000 square feet of operating space with an expected yield of 10,000 pounds of high-quality flower annually. RWB anticipates this annual yield will generate $30 million in additional revenue. RWBFL also successfully produced the first batch of chocolates from its new Sanderson production facility, announced in early September. A recent article reads, “The three-phased development strategy aligns perfectly with [RWB CEO Brad] Rogers’ summary of the company’s focus for the remainder of 2021 and throughout 2022. ‘The company will focus on the continued growth of our top-line revenue and bottom-line results through expansion of our house of brands that continue to gain momentum, fortification of our vertically integrated businesses and the synergies from our M&A success,’ stated Rogers.” To view the full article, visit: https://cnw.fm/8yJCw.

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Tuesday’s trading session at $0.3556, off by 3.6314%, on 387,482 volume. The average volume for the last 3 months is 387,482 and the stock's 52-week low/high is $0.3354/$1.65.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading